On November 4, 2015, the United States Food and Drug Administration (FDA) approved NUCALA (mepolizumab) subcutaneous (SC) injection as an add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

When was Mepolizumab discovered?

First approved in 2015 for severe eosinophilic asthma, mepolizumab is the first-in-class monoclonal antibody that targets IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils.

Is Nucala FDA approved?

GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).